Lacosamide Tablet, Film Coated
Product Images NDC 70518-4561

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 70518-4561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Lacosamide 100mg 70518 4561 00)

This is a description of Lacosamide 100mg tablets, a Schedule C-V controlled substance. Each box contains 30 tablets. The tablets are yellow in color. The medication is manufactured by Ascend Labs, LLC, and repackaged by RemedyRepack Inc. It is advised to keep this medication out of the reach of children and store it at 20-25°C (68-77°F). A caution is given against transferring the drug to anyone other than the prescribed patient due to federal law restrictions. Detailed dosing instructions are provided in the insert.*

FDA Label Image

Remedy_label (Remedy Label)

This is a description of a Lacosamide Tablet C-V, containing 100 mg, with specific instructions on usage and storage. It includes information like the NDC number, manufacturer details, caution regarding transferring the drug, and guidance on keeping it away from children. The drug is noted as being for prescription-only use.*

FDA Label Image

Laco-fig1.jpg (Laco Fig1)

This text shows Figure 1, illustrating the median percent reduction in seizure frequency per 28 days from baseline to the maintenance phase based on different doses. The chart displays data related to the reduction in seizure frequency with varying doses of a medication called Lacosamide compared to a placebo.*

FDA Label Image

Laco-fig2.jpg (Laco Fig2)

This text provides information on the Responder Rate for Lacosamide and Placebo groups in Studies 2, 3, and 4. It includes the proportion of patients in each group for different doses of Lacosamide. The data presented may be helpful for analyzing the efficacy of Lacosamide in comparison to the placebo in clinical studies.*

FDA Label Image

Laco-fig3-a (Laco Fig3 A)

This information shows the proportion of patients taking Lacosamide with a risk reduction of 45.2%. The study consisted of 118 patients, with 96 at risk in the Lacosamide group. The p-value was 0.001, indicating a statistically significant result. The hazard ratio was 0.548 with a 95% confidence interval of [0.381, 0.788]. This data suggests a potential benefit of using Lacosamide in the patient population studied.*

FDA Label Image

Laco-str (Laco Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.